{"id":6629,"date":"2019-11-28T16:27:57","date_gmt":"2019-11-28T10:57:57","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=6629"},"modified":"2022-08-16T10:32:32","modified_gmt":"2022-08-16T05:02:32","slug":"recent-pharma-happenings-for-sanofis-taurx-pfizer-novartis","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sanofis-taurx-pfizer-novartis","title":{"rendered":"Toujeo to treat Type 1 Diabetes; TauRx for Alzheimer\u2019s patients"},"content":{"rendered":"\n

Sanofi\u2019s Toujeo has received\nFDA recommendation for its expanded use in Type 1 Diabetes. <\/strong><\/h3>\n\n\n\n

Toujeo is an insulin glargine\ninjection to control the highs and lows of blood sugar in the body. Indicated\nto be used in adults and paediatric patients of age six and older. <\/p>\n\n\n\n

Earlier, the injection was\nconsidered suitable and approved only for patients age 18 and older. The\nexpanded approval came on the basis of successful results of the study EDITION\nJUNIOR. It was the first randomized, controlled study which compared the\nefficacy of Toujeo (insulin glargine 300 Units\/mL) with Gla-100 (insulin\nglargine 100 Units\/mL). Toujeo was successful in lowering the blood sugar in\nthe period of six months. <\/p>\n\n\n\n

Type 1 Diabetes <\/a>incidence is rising worldwide. Around 1.25 million Americans have Type 1 diabetes. Moreover, the diagnosed Type 1 diabetes<\/a> patients will reach 5 Million by 2050, as per according to a study. <\/p>\n\n\n\n

Sanofi also has another insulin\ninjection which it sells under the name of Lantus which is less concentrated (insulin\nglargine 100 Units\/mL) as compared to Toujeo. Upon the approval of Toujeo,\nsales of Lantus dropped due to the efficacy of the former one. The year 2018\nrevealed the revenue Toujeo made for the company was around USD 840 Million. <\/p>\n\n\n\n

Pfizer, Novartis and eleven other drugmakers have announced to invest a hefty amount of USD 2Million to advance Gene therapy. <\/strong><\/h3>\n\n\n\n

The amount in total invested by Pfizer and Novartis individually is USD 600 Million and USD 500 Million respectively. The drug makers have planned to use the amount to make their own manufacturing units to develop the gene therapies to treat indications. <\/p>\n\n\n\n

Gene therapies<\/a> are novel treatment approaches to cure chronic diseases like cancer, beta-thalassemia, hepatitis, and cystic fibrosis. The treatment approach is an advanced way, which applies the use of the latest technology in it. Thus, the cost incurred is too high for both the therapy developing pharma companies and the patient undergoing the therapy. <\/p>\n\n\n\n

Successfully approved gene therapies such as that of Bluebird Bio, Zynteglo, Novartis\u2019 Zolgensma and Merck\u2019s Keytruda are some of the blockbusters that promises a bright future and a disease-free life. However, they are attached to a huge price that not everyone is able to afford. <\/p>\n\n\n\n

As per the pharma companies, setting\nup of their manufacturing unit will help them cut the expenses, prevent the\ndelays due to contract manufacturing plants and monitor the standard norms of\nmanufacturing therapies as per the US FDA standards. <\/p>\n\n\n\n

TauRx, a leader in Alzheimer\u2019s disease, has recently announced positive results for its drug hydromethylthionine (LMTM) in Alzheimer\u2019s disease.<\/strong><\/h3>\n\n\n\n

The analysis of trials is published in the Journal of Alzheimer\u2019s Disease<\/em>.<\/p>\n\n\n\n

According to the Alzheimer\u2019s Association, more women than men have Alzheimer\u2019s or other dementias.<\/p>\n\n\n\n

Alzheimer’s disease attacks brain cells and neurotransmitters (chemicals that carry messages between brain cells), affecting the way your brain functions, your memory and the way you behave. It is also the most common form of dementia.<\/p>\n\n\n\n

Previously known as LMTM, Hydromethylthionine is a WHO-approved drug, which blocks the collection of tau proteins in the brain. The company focused on the different treatment<\/a> doses and pharmacological activities of the drug in the brain. The trials recruited more than 1000 patients suffering from mild-to-moderate Alzheimer\u2019s <\/a>disease. <\/p>\n","protected":false},"excerpt":{"rendered":"

Sanofi\u2019s Toujeo has received FDA recommendation for its expanded use in Type 1 Diabetes. Toujeo is an insulin glargine injection to control the highs and lows of blood sugar in the body. Indicated to be used in adults and paediatric patients of age six and older. Earlier, the injection was considered suitable and approved only […]<\/p>\n","protected":false},"author":1,"featured_media":6632,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[17629,258,349,423,460,639,5789,533,17848,17847,17722],"industry":[17225],"therapeutic_areas":[17240,17245],"class_list":["post-6629","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-alzheimers-disease","tag-gene-therapy","tag-latest-pharma-news","tag-novartis","tag-pfizer","tag-pharma-news","tag-recent-pharma-news","tag-sanofi","tag-taurx","tag-toujeo","tag-type-1-diabetes","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-neurology"],"acf":[],"yoast_head":"\nSanofi\u2019s Toujeo; Investment in gene therapy; TauRx's hydromethylthionine<\/title>\n<meta name=\"description\" content=\"Pfizer, Novartis and eleven other drugmakers have announced to invest a hefty amount of USD 2Million to advance Gene therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sanofis-taurx-pfizer-novartis\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi\u2019s Toujeo; Investment in gene therapy; TauRx's hydromethylthionine\" \/>\n<meta property=\"og:description\" content=\"Pfizer, Novartis and eleven other drugmakers have announced to invest a hefty amount of USD 2Million to advance Gene therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sanofis-taurx-pfizer-novartis\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-11-28T10:57:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-08-16T05:02:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/15161527\/Pharma-News-28-Nove.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sanofi\u2019s Toujeo; Investment in gene therapy; TauRx's hydromethylthionine","description":"Pfizer, Novartis and eleven other drugmakers have announced to invest a hefty amount of USD 2Million to advance Gene therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sanofis-taurx-pfizer-novartis","og_locale":"en_US","og_type":"article","og_title":"Sanofi\u2019s Toujeo; Investment in gene therapy; TauRx's hydromethylthionine","og_description":"Pfizer, Novartis and eleven other drugmakers have announced to invest a hefty amount of USD 2Million to advance Gene therapy.","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sanofis-taurx-pfizer-novartis","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-11-28T10:57:57+00:00","article_modified_time":"2022-08-16T05:02:32+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/15161527\/Pharma-News-28-Nove.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sanofis-taurx-pfizer-novartis","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sanofis-taurx-pfizer-novartis","name":"Sanofi\u2019s Toujeo; Investment in gene therapy; TauRx's hydromethylthionine","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sanofis-taurx-pfizer-novartis#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sanofis-taurx-pfizer-novartis#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/15161527\/Pharma-News-28-Nove.jpg","datePublished":"2019-11-28T10:57:57+00:00","dateModified":"2022-08-16T05:02:32+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Pfizer, Novartis and eleven other drugmakers have announced to invest a hefty amount of USD 2Million to advance Gene therapy.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sanofis-taurx-pfizer-novartis"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sanofis-taurx-pfizer-novartis#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/15161527\/Pharma-News-28-Nove.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/15161527\/Pharma-News-28-Nove.jpg","width":772,"height":482,"caption":"Pharma News"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/15161527\/Pharma-News-28-Nove.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alzheimer\u0092s Disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gene therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Novartis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sanofi<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">TauRx<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Toujeo<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Type 1 Diabetes<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Alzheimer\u0092s Disease<\/span>","<span class=\"advgb-post-tax-term\">Gene therapy<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">Novartis<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>","<span class=\"advgb-post-tax-term\">Sanofi<\/span>","<span class=\"advgb-post-tax-term\">TauRx<\/span>","<span class=\"advgb-post-tax-term\">Toujeo<\/span>","<span class=\"advgb-post-tax-term\">Type 1 Diabetes<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 4 years ago"},"absolute_dates":{"created":"Posted on Nov 28, 2019","modified":"Updated on Aug 16, 2022"},"absolute_dates_time":{"created":"Posted on Nov 28, 2019 4:27 pm","modified":"Updated on Aug 16, 2022 10:32 am"},"featured_img_caption":"Pharma News ","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6629","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=6629"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6629\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/6632"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=6629"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=6629"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=6629"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=6629"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=6629"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}